CALCIUM GLUCONATE INJECTION, USP 10% SOLUTION

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Aktiv bestanddel:

CALCIUM GLUCONATE

Tilgængelig fra:

BAXTER CORPORATION

ATC-kode:

B05XA19

INN (International Name):

CALCIUM GLUCONATE

Dosering:

100MG

Lægemiddelform:

SOLUTION

Sammensætning:

CALCIUM GLUCONATE 100MG

Indgivelsesvej:

INTRAVENOUS

Enheder i pakken:

15G/50G

Recept type:

Ethical

Produkt oversigt:

Active ingredient group (AIG) number: 0108566002; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2021-12-08

Produktets egenskaber

Calcium Gluconate Injection, USP 10% - Prescribing Information
Page 1 of 9
PRESCRIBING INFORMATION
CALCIUM GLUCONATE INJECTION, USP 10%
Solution, 100 mg / mL (0.446 mEq / mL)
For Intravenous Use
Pharmacy bulk package: 50 000 mg per 500 mL
ATC Code: B05BB01
Electrolyte Replenisher
BAXTER CORPORATION
7125 Mississauga Road
Mississauga, ON L5N 0C2
Date of Preparation:
December 8, 2021
Submission
Control No: 242725
Baxter and Clearflex are trademarks of Baxter International Inc.
Calcium Gluconate Injection, USP 10% - Prescribing Information
Page 2 of 9
TABLE OF CONTENTS
1.
INDICATIONS
.............................................................................................................
3
2.
CONTRAINDICATIONS
.............................................................................................
3
3.
DOSAGE AND
ADMINISTRATION...........................................................................
3
3.1
Recommended Dose and Dosage
Adjustment..........................................................3
3.2
Administration
.......................................................................................................4
3.3
Reconstitution
........................................................................................................5
4.
OVERDOSAGE
............................................................................................................
5
5.
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................. 5
6.
WARNINGS AND PRECAUTIONS
............................................................................
6
6.1
Special Populations
................................................................................................7
6.1.1
Pregnant
Women....................................................................................................7
6.1.2
Breast-feeding........................................................................................................7
7.
ADVERSE REACTIONS
..............................................................................